We believe now is the time to drive the next generation of cancer breakthroughs in Australia.

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 30 countries/regions around the world. With over 120 years of scientific expertise, our story here has recently begun. In April 2023, we embarked on an exciting new chapter in Australia, with a mission to redefine cancer treatment through our proprietary antibody drug conjugate (ADC) technology. We have built a presence from the ground up, one that is designed intentionally to meet the unique needs of this country and its people.